Search for: "Roche v. Mark Producing"
Results 21 - 40
of 40
Sorted by Relevance
|
Sort by Date
5 Jan 2008, 6:00 am
You can separately subscribe to the IP Think Tank Global week in Review at [feeds.feedburner.com]GlobalComing out of copyright - some notable deaths from 1937: (IPKat),Design patents: No longer the province of individual inventors: (Patently O),Fail fast, ready fire aim and Stanford v Cal: (IP Think Tank),Walls, Alexander the Great and Partha Bose: (IP Think Tank),A fair use primer for online content creators: (Ars Technica)ISO moves to… [read post]
9 Jan 2014, 1:37 pm
Hoffman-La Roche, Inc., 2010 WL 3034453, at *22 (N.J. [read post]
21 Dec 2009, 5:24 am
– still awaiting decision on radio royalties (Spicy IP) Lok Sabha passes Trade Mark (Amendment) Bill 2009 – finally! [read post]
15 Jul 2009, 5:15 am
IPAB rejects Novartis’ patent application for Glivec (Intellectual Property Watch) Lescol (Fluvastatin) – Netherlands: No interim relief pending appeal against invalidity, rules District Court of The Hague: Novartis v Mylan and Actavis (PatLit) Levaquin (Levoflaxacin) – Canada: FCA holds generics raising allegations similar to those of previous generics allowed their day in court: Apotex v Janssen-Ortho (Global IP Watch) Lexapro (Escitalopram)… [read post]
20 Aug 2010, 6:27 am
Hoffmann-La Roche, Inc. v. [read post]
7 May 2009, 6:08 am
Roche Laboratories, Inc., 243 F.Supp.2d 672, 677 (W.D. [read post]
19 Nov 2013, 12:02 pm
” Wahl v. [read post]
13 Jun 2008, 3:40 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ECJ rules trade mark holders cannot stop honest comparative advertising: O2 Holdings Limited and O2 (UK) Limited v Hutchinson 3G UK Limited: (Out-Law), (Catch Us If You Can!!!) [read post]
23 Feb 2011, 10:18 pm
Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. [read post]
11 Jan 2008, 9:00 am
: (IP Spotlight)PharmaIndia: Trade mark assignment under scrutiny in a case of deceptive similarity - Doctor Morepen Limited v Yash Pharma Laboratories Limited: (Mondaq),Arrow v Merck - An early route to market for generics? [read post]
19 Sep 2008, 6:00 pm
: (IP finance), United States: An open letter for the General Counsel of the PTO on your San Diego presentation next week: (Hal Wegner), United States: Cocoa genome: breaking intellectual property barriers: (Thomson Reuters Scientific), Vietnam: Patentability of second medical use claims in Vietnam is again questionable: (Trung Truc JSC) Pharma & Biotech - Products Allegra (Fexofenadine) - Canada: Motion for summary judgment of noninfringement dismissed in patent infringement… [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human Genome Sciences:… [read post]
15 Feb 2008, 9:00 am
: (IP finance),Global - Trade Marks / Domain Names / BrandsICANN supports Google’s fight against domain-tasting: (Class 46),Global - PatentsSoftware patents and startup innovators: (Technological Innovation and Intellectual Property),Co-inventor: yes or no? [read post]
13 Jun 2008, 12:12 pm
Hoffmann-La Roche Inc., 891 A.2d 1229 (N.J. [read post]
12 Dec 2014, 5:06 am
Same crystal form obtained directly from the reaction mixture used to synthesise the compound, said crystal form crashing out of solution on work-up.Follow up comment:Question mark over my crystal form example would be whether the form is sufficiently characterised by the data, therefore not requiring the process step. [read post]
28 Apr 2011, 3:18 pm
Brown v. [read post]
19 Mar 2022, 2:09 pm
The FDA acknowledges, for instance, that the acceptable intake is set to mark “a small theoretical increase in risk,” and a “highly hypothetical concept that should not be regarded as a realistic indication of the actual risk,” and thus not an actual risk.[9] The corresponding hypothetical or theoretical risk to the acceptable intake level is clearly small when compared with the human’s lifetime probability of developing cancer (which the FDA states is greater… [read post]
18 Feb 2010, 10:34 am
” Id.; accord Heckler v. [read post]
25 May 2011, 11:46 pm
Therasense v. [read post]
8 Sep 2015, 5:08 pm
First, in a July 8, 2015 decision in Acevedo v. [read post]
